Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Glioma | Research

Antitumor effect of IL-12 gene-modified bone marrow mesenchymal stem cells combined with Fuzheng Yiliu decoction in an in vivo glioma nude mouse model

Authors: Jianjun Wu, Shoupin Xie, Hailong Li, Yanxia Zhang, Jia Yue, Chunlu Yan, Kai Liu, Yongqi Liu, Rui Xu, Guisen Zheng

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Glioma is a complex cancer with a high morbidity and high mortality. Bone marrow mesenchymal stem cells (BMSCs) have shown promise as an excellent cell/drug delivery vehicle for gene-targeted therapy; however, maintaining genetic stability and biological activity remains difficult. Furthermore, whether BMSCs support or inhibit tumor growth remains debated. This study investigated whether a traditional Chinese medicine fomular, Fuzheng Yiliu decoction (FYD) had a synergistic antitumor effect with IL-12 gene-modified BMSCs in glioma-bearing nude mice

Methods

The lentivirus-mediated IL-12 gene was transfected into primarily cultured BMSCs. A total of 72 BALB/c nude mice were used to establish xenograft models with glioma U251 cells and were divided into groups (n = 12) including blank control group, nude mouse model group (model group), lentiviral transfection of BMSC group with no gene loading (BMSC group), IL-12 lentivirus-transfected BMSC group (IL-12 + BMSC group), FYD treatment group (FYD group), and FYD treatment in IL-12 lentivirus-transfected BMSC group (FYD + IL-12 + BMSC group).. After treatment for 14 days, all mice were sacrificed to collect tumor tissue and serum for more detection, such as distribution of BMSCs, cell apoptosis in xenograft tumors, serum IL-12 and INF-γ levels, mouse weight and tumor volume were measured

Results

There were significantly more apoptotic cells in tumor tissue in IL-12 gene transfected group, FYD treatment group and FYD combining with IL-12 gene transfected group than that in the model group (P < 0.05). The FYD + IL-12 + BMSC group showed significantly higher Bax and lower Bcl-2 expression (P < 0.05), and serum IL-12 and INF-γ levels (P < 0.05) were higher than that in all other groups. After the intervention, this group also showed a strong inhibitory effect against tumor growth (P < 0.05)

Conclusions

This study suggested FYD treatment combined with IL-12 gene-modified BMSCs shows synergistic antitumor effect in glioma-bearing nude mice.
Literature
1.
2.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.PubMedCrossRef
3.
Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer. 2010;116:2519–30.PubMedCrossRef
4.
Kim SW, Lee YK, Hong JH, Park JY, Choi YA, Lee DU, Choi J, Sym SJ, Kim SH, Khang D. Mutual destruction of deep lung tumor tissues by nanodrug-conjugated stealth mesenchymal stem cells. AdvSci. 2018;5:1700860.
5.
Zhang S, Liu Y, Derakhshanfar S, He W, Huang Q, Dong S, Rao J, Luo GX, Zhong W, Liao W, et al. Polymer self-assembled BMSCs with cancer tropism and programmed homing. AdvHealthc Mater. 2018;7:e1800118.
6.
Du J, Zhou L, Chen X, Yan S, Ke M, Lu X, Wang Z, Yu W, Xiang AP. IFN-gamma-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol. 2012;44:1305–14.PubMedCrossRef
7.
Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol. 2009;182:7963–73.PubMedCrossRef
8.
Zhang TY, Huang B, Yuan ZY, Hu YL, Tabata Y, Gao JQ. Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection. Nanomedicine. 2014;10:257–67.PubMedCrossRef
9.
Wei Z, Chen N, Guo H, Wang X, Xu F, Ren Q, Lu S, Liu B, Zhang L, Zhao H. Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J ExpClin Cancer Res. 2009;28:141.
10.
11.
Zhang L, Su XS, Ye JS, Wang YY, Guan Z, Yin YF. Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system. Stem Cell Res Ther. 2015;6:45.PubMedPubMedCentralCrossRef
12.
Mognetti B, La Montagna G, Perrelli MG, Pagliaro P, Penna C. Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1alpha. J Cell Mol Med. 2013;17:287–92.PubMedPubMedCentralCrossRef
13.
Shirjang S, Mansoori B, Solali S, Hagh MF, Shamsasenjan K. Toll-like receptors as a key regulator of mesenchymal stem cell function: an up-to-date review. Cell Immunol. 2017;315:1–10.PubMedCrossRef
14.
Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol. 2007;179:1549–58.PubMedCrossRef
15.
Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer. 2009;115:13–22.PubMedCrossRef
16.
Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, Brinchmann JE, Collas P. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol. 2008;52:1033–42.PubMedCrossRef
17.
El-Badawy A, Ghoneim MA, Gabr MM, Salah RA, Mohamed IK, Amer M, El-Badri N. Cancer cell-soluble factors reprogram mesenchymal stromal cells to slow cycling, chemoresistant cells with a more stem-like state. Stem Cell Res Ther. 2017;8:254.PubMedPubMedCentralCrossRef
18.
Gjerstorff M, Burns JS, Nielsen O, Kassem M, Ditzel H. Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. Am J Pathol. 2009;175:314–23.PubMedPubMedCentralCrossRef
19.
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK, Tang W. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4:297–307.PubMed
20.
Liu XP, Ming HX, Li PQ. Intervention effect of pinelliae decoction for purging stomach-fire on malignant transformation of bone marrow mesenchymal stem cells in the gastric cancer microenvironment. Am J Transl Res. 2016;8:2937–46.PubMedPubMedCentral
21.
Ma YX, Liu LQ, Qin LM, Zuo GM, Wang Y. Xuefuzhuyu decoction containing serum in vitro induced expressions of desmin and alpha-actin: an experimental research. Chin J IntegrTradit West Med. 2013;33:1252.
22.
Ke B, Shi L, Xu Z, Wu G, Gong Y, Zhu L, Wang Y, Ouyang H, Wang X. Flavored GuiluErxian decoction inhibits the injury of human bone marrow mesenchymal stem cells induced by cisplatin. Cell MolBiol. 2018;64:58–64.
23.
Yang P, Chen A, Qin Y, Yin J, Cai X, Fan YJ, Li L, Huang HY. Buyanghuanwu decoction combined with BMSCs transplantation promotes recovery after spinal cord injury by rescuing axotomized red nucleus neurons. J Ethnopharmacol. 2019;228:123–31.PubMedCrossRef
24.
Wang XX, Zhao JX, Chen R. Effect of FuzhengYiliu granule contained-serum from tumor bearing mice on apoptotic rate, free radicals content and mitochondrial membrane potential of hepatoma cell lines H22 in vitro. Chin J IntegrTradit West Med. 2007;27:343.
25.
Zhao JX. Effects of FuzhengYiliu Granules on apoptotic rate and mitochondrial membrane potential of hepatocellular carcinoma cell line H22 from mice. Chin J IntegrTradit West Med. 2006;4:271–4.CrossRef
26.
Zhao JX, Li XF, Wang XX. Effects of body-resistance strengthening and tumor-suppressing granules on immune adhesion function of red blood cells and expession of metastasis protein CD44 in tumor cells of patients with esophageal carcinoma. World J Gastroenterol. 2007;13:4360–4.PubMedPubMedCentralCrossRef
27.
Zeng L, Ma Z, Wu J, Wang Z, Zhou S, Wang X. The effect of FuzhengYiliu decoction containing serum on proliferation, cycle and apoptosis of bone marrow mesenchymal stem cells in glioma environment. J Lanzhou Univ. 2016;42:7–13.
28.
IoLA R. Guide for the care and use of laboratory animals. Publication. 2011;327:963–5.
29.
Cima G. AVMA Guidelines for the Euthanasia of Animal 2013 Edition. J Am Vet Med Assoc. 2013;242:715–6.
30.
Xi G, Best B, Mania-Farnell B, James CD, Tomita T. Therapeutic potential for bone morphogenetic protein 4 in human malignant glioma. Neoplasia. 2017;19:261–70.PubMedPubMedCentralCrossRef
31.
Qing Z, Wei X, Dong-ye Y, Bing-zhou X, Wan-wan W, Ahmed A, Nan-xiang X, Xiao-bing J, Hong-yang Z, Peng F. Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas. Stem Cell Research & Therapy. 2017;9:228.
32.
Dunn-Pirio AM, Vlahovic G. Immunotherapy approaches in the treatment of malignant brain tumors. Cancer. 2017;123:734–50.PubMedCrossRef
33.
Xiaoling W, Jian-Qing G, Xumei O, Junbo W, Xiaoyi S, Yuanyuan L. Mesenchymal stem cells loaded with paclitaxel–poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. International Journal of Nanomedicine. 2018;13:5231–48.CrossRef
34.
Shi S, Min Z, Rui G, Ying M, Biao L: Bone Marrow Derived Mesenchymal Stem Cell-Mediated Dual-gene Therapy for Glioblastoma. Human Gene Therapy:hum.2018.2092-.
35.
Mooney R, Hammad M, Batalla-Covello J, Abdul Majid A, Aboody KS. Concise review: neural stem cell-mediated targeted cancer therapies. Stem Cells Transl Med. 2018;7:740–7.PubMedPubMedCentralCrossRef
36.
Stepanenko AA, Chekhonin VP: Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? Cancers (Basel) 2018, 10.
37.
Matushansky I, Hernando E, Socci ND, Mills JE, Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J ClinInvestig. 2007;117:3248–57.
38.
Zhao Y, Chen J, Dai X, Cai H, Ji X, Sheng Y, Liu H, Yang L, Chen Y, Xi D. Human glioma stem-like cells induce malignant transformation of bone marrow mesenchymal stem cells by activating TERT expression. Oncotarget. 2017;8:104418.PubMedPubMedCentralCrossRef
39.
Sawada R, Matsuoka A, Matsuda Y, Tsuchiya T. Change in characteristics of human mesenchymal stem cells during the in vitro culture. YakugakuZasshi. 2008;128:1851–6.
40.
Zheng X, Wu F, Lin X, Shen L, Feng Y. Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine. Drug Deliv. 2018;25:398–416.PubMedPubMedCentralCrossRef
41.
Pu WL, Sun LK, Gao XM, Ruegg C, Cuendet M, Hottiger MO, Zhou K, Miao L, Zhang YS, Gebauer M. Targeting tumor-associated macrophages by anti-tumor Chinese materiamedica. Chin J Integr Med. 2017;23:723–32.PubMedCrossRef
42.
Fu’er L, Guangying H. Investigation on therapeutic mechanisms of three principles of traditional Chinese medicine for treating malignant tumors. Chin J Integr Med. 2003;9:237–40.CrossRef
43.
Kai J, Yang D: Clinical study of the combined treatment with Chinese traditional medicine and interventional chemotherapy on malignant tumor. Modern J Integr Tradit Chin West Med 2009.
44.
Chen XZ, Cao ZY, Liao LM, Liu ZZ, Jian D. Application of serum pharmacology in evaluating the antitumor effect of FuzhengYiliu Decoction from Chinese medicine. Chin J Integr Med. 2013;20:450.PubMedCrossRef
45.
Wei F, xin LQ, shu CB, bei ZB, yan YG, long CC, ming LW, Lin Y, qiu ZB, jun YX: Study on Tumor Suppressing Effect of Fuzheng Yiliu Decoction on Prostate Cancer Bearing Nude Mice and Expression of Serum IL-2. Guiding Journal of Traditional Chinese Medicine and Pharmacy 2018.
46.
Jianjun W, Long Z, Yongqi L, Jia Y, Zhanjun M, Zhuanling W, Shuning Z, Xuexi W: Effects of Fuzheng Yiliu Fang on Telomerase Activity and P53 Expression in BMSCs in C6 Micro-environment. Chinese Journal of Traditional Medical Science and Technology 2017.
47.
Chao S, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, Leiner I, Li MO, Frenette PS, Pamer EG. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity. 2011;34:590–601.CrossRef
48.
49.
Yang SX, Wei W-S, Ouyan Q-W, Jiang Q-H, Zou Y-F, Qu W, Tu J-H, Zhou Z-B, Ding H-L, Xie C-W. Interleukin-12 activated CD8+ T cells induces apoptosis in breast cancer cells and reduces tumor growth. Biomed Pharmacother. 2016;84:1466–71.PubMedCrossRef
50.
51.
Skala E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokinska H, Sliwinski T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. J Pharm Pharmacol. 2016;68:1454–64.PubMedCrossRef
Metadata
Title
Antitumor effect of IL-12 gene-modified bone marrow mesenchymal stem cells combined with Fuzheng Yiliu decoction in an in vivo glioma nude mouse model
Authors
Jianjun Wu
Shoupin Xie
Hailong Li
Yanxia Zhang
Jia Yue
Chunlu Yan
Kai Liu
Yongqi Liu
Rui Xu
Guisen Zheng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02809-2

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Research

Sex-specific plasma lipid profiles of ME/CFS patients and their association with pain, fatigue, and cognitive symptoms

Research

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection

Research

Lactobacillus paracasei R3 protects against dextran sulfate sodium (DSS)-induced colitis in mice via regulating Th17/Treg cell balance

Research

Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS

Research

Collaborative relationships in translational medical research among Chinese clinicians: an internet-based cross-sectional survey

Research

Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits